



Tenaya Therapeutics to Participate in Upcoming October Investor and Industry Conferences

September 29, 2022

SOUTH SAN FRANCISCO, Calif., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, announced today that Faraz Ali, Chief Executive Officer, is scheduled to participate in the Chardan 6th Annual Genetic Medicines Conference and the Alliance for Regenerative Medicine's Cell and Gene Meeting on the Mesa. Details of participation are as follows:

[Chardan's 6th Annual Genetic Medicines Conference](#)

Fireside chat

Date: October 4, 2022

Time: 11:00 a.m. ET

A webcast of the Chardan event will be available by visiting the Investors section of [Tenaya's website](#). A replay of the webcast will be available on the Tenaya website for approximately 30 days following the conference.

[Alliance for Regenerative Medicine's Cell and Gene Meeting on the Mesa](#)

Company Presentation

Date: Tuesday, October 11, 2022

Time: 11:45 a.m. PT

Panel: The Future of Gene Delivery: In Search of Game-Changing In Vivo Applications

Date: Thursday, October 13, 2022

Time: 11:00 a.m. – 12:00 p.m. PT

A recording of the Meeting on the Mesa event will be available on the conference platform for on-demand viewing by registered participants.

About Tenaya Therapeutics

Tenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver curative therapies that address the underlying drivers of heart disease. Founded by leading cardiovascular scientists from Gladstone Institutes and the University of Texas Southwestern Medical Center, Tenaya is developing therapies for rare genetic cardiovascular disorders, as well as for more prevalent heart conditions, through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. For more information, visit www.tenayatherapeutics.com.

Investors

Michelle Corral

Tenaya Therapeutics

IR@tenayathera.com

Media

Wendy Ryan

Ten Bridge Communications

wendy@tenbridgecommunications.com